The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

EXCLUSIVE: New mum Zara was shattered when told she had bowel cancer, but a new drug trial at The Christie in Manchester has ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody ® and Moditope ® active immunotherapies to treat cancer, announces further positive data from the ongoing Phase 2 SCOPE trial of ...

AEMD READ THE FULL AEMD RESEARCH REPORT Data Safety Monitoring Board Recommends Progressing Trial Without Modification Aethlon Medical’s (NASDAQ:AEMD) current primary focus is on researching lead ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

Although anti-PD-1 therapy, alone or in combination with an anti-CTLA-4 agent, has become the first-line standard of care for ...